Supplementary Table 1 Clinicopathologic features of 5 patients used for RNA-seq.
Aim: To explore the expression profiles of lncRNAs and identify novel lncRNAs as biomarkers for early diagnosis and therapy of hepatocellular carcinoma (HCC). Materials & methods: Expression profiles of lncRNAs and mRNAs in five paired HCC and adjacent normal tissues were obtained by RNA-seq. Eight lncRNAs, including two novel liver-specific lncRNAs (NONHSAT059247.2 and NONHSAT013897.2), were validated in another 74 pairs of HCC and adjacent normal tissues by qRT-PCR. Results: The results of qRT-PCR showed that NONHSAT252133.1, NONHSAT112116.2, and NONHSAT242657.1 were significantly upregulated in HCC tissues, whereas NONHSAT169790.1, NONHSAT059247.2, and NONHSAT013897.2 were significantly downregulated. Two liver-specific lncRNAs demonstrated excellent diagnostic performance: NONHSAT059247.2 (AUC=0.941, 95% CI: 0.902-0.979, P<0.0001), NONHSAT013897.2 (AUC=0.944, 95% CI: 0.906-0.983, P<0.0001).